MX363558B - Composiciones farmaceuticas que comprenden flurbiprofeno. - Google Patents

Composiciones farmaceuticas que comprenden flurbiprofeno.

Info

Publication number
MX363558B
MX363558B MX2015002946A MX2015002946A MX363558B MX 363558 B MX363558 B MX 363558B MX 2015002946 A MX2015002946 A MX 2015002946A MX 2015002946 A MX2015002946 A MX 2015002946A MX 363558 B MX363558 B MX 363558B
Authority
MX
Mexico
Prior art keywords
flurbiprofen
pharmaceutical compositions
coughs
nsaid
ibuprofen
Prior art date
Application number
MX2015002946A
Other languages
English (en)
Other versions
MX2015002946A (es
Inventor
Shea Tim
Shephard Adrian
Smith Gary
Aspley Sue
P Schachtel Bernard
Original Assignee
Reckitt Benckiser Healthcare International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47137098&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX363558(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Reckitt Benckiser Healthcare International Ltd filed Critical Reckitt Benckiser Healthcare International Ltd
Publication of MX2015002946A publication Critical patent/MX2015002946A/es
Publication of MX363558B publication Critical patent/MX363558B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Abstract

La invención actual proporciona un NSAID tal como ibuprofeno o flurbiprofeno, o una sal farmacéuticamente aceptable del mismo para uso en el tratamiento tópico de tos, especialmente tos seca.
MX2015002946A 2012-09-07 2013-09-09 Composiciones farmaceuticas que comprenden flurbiprofeno. MX363558B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261697901P 2012-09-07 2012-09-07
GBGB1215988.5A GB201215988D0 (en) 2012-09-07 2012-09-07 Pharmaceutical compositions comprising flurbiprofen
PCT/US2013/058685 WO2014039939A1 (en) 2012-09-07 2013-09-09 Pharmaceutical compositions comprising flurbiprofen

Publications (2)

Publication Number Publication Date
MX2015002946A MX2015002946A (es) 2015-06-02
MX363558B true MX363558B (es) 2019-03-27

Family

ID=47137098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002946A MX363558B (es) 2012-09-07 2013-09-09 Composiciones farmaceuticas que comprenden flurbiprofeno.

Country Status (12)

Country Link
US (5) US20150231063A1 (es)
EP (1) EP2892528B1 (es)
KR (2) KR20150048890A (es)
AU (1) AU2013312259B2 (es)
BR (1) BR112015004115A2 (es)
ES (1) ES2742034T3 (es)
GB (1) GB201215988D0 (es)
MX (1) MX363558B (es)
PL (1) PL2892528T3 (es)
RU (2) RU2019102890A (es)
WO (1) WO2014039939A1 (es)
ZA (1) ZA201501553B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025019A (en) * 1984-04-09 1991-06-18 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US5322689A (en) * 1992-03-10 1994-06-21 The Procter & Gamble Company Topical aromatic releasing compositions
US20030206942A1 (en) 1998-09-25 2003-11-06 Neema Kulkarni Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent
US6846495B2 (en) * 1999-01-11 2005-01-25 The Procter & Gamble Company Compositions having improved delivery of actives
US20060241175A1 (en) * 2002-09-27 2006-10-26 Joseph Schwarz Vehicle for topical delivery of anti-inflammatory compounds
GB2423710A (en) * 2005-03-01 2006-09-06 Boots Healthcare Int Ltd Lozenge production process
ES2393128T3 (es) * 2006-10-20 2012-12-18 Bayer Consumer Care Ag Ibuprofeno contra la tos
GB2453770A (en) * 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent
AU2011308865B2 (en) * 2010-09-29 2017-01-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
GB201021267D0 (en) * 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation

Also Published As

Publication number Publication date
RU2019102890A (ru) 2019-05-07
RU2015112586A (ru) 2016-10-27
US20190070101A1 (en) 2019-03-07
MX2015002946A (es) 2015-06-02
ZA201501553B (en) 2017-08-30
KR20200131913A (ko) 2020-11-24
PL2892528T3 (pl) 2019-11-29
US20220008331A1 (en) 2022-01-13
EP2892528A4 (en) 2016-04-13
US20200163871A1 (en) 2020-05-28
KR20150048890A (ko) 2015-05-07
US20180110723A1 (en) 2018-04-26
AU2013312259A1 (en) 2015-04-09
EP2892528A1 (en) 2015-07-15
AU2013312259B2 (en) 2018-06-07
EP2892528B1 (en) 2019-05-15
GB201215988D0 (en) 2012-10-24
WO2014039939A1 (en) 2014-03-13
BR112015004115A2 (pt) 2017-07-04
ES2742034T3 (es) 2020-02-12
US20150231063A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
GB201106750D0 (en) Novel compounds
PH12016500316A1 (en) Improved adenovirus formulations
PH12016501122A1 (en) Delayed release compositions of linaclotide
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
GB201106743D0 (en) Novel compounds
MX348823B (es) Formulaciones estables de linaclotida.
PH12014501991B1 (en) Phenicol antibacterials
IL227626A0 (en) A compound of 17-il and γ-ifn inhibitors, preparations containing them and their uses
IN2014DN10670A (es)
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
BR112014025041B8 (pt) Composição farmacêutica
EA033171B1 (ru) Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
IN2014DN11078A (es)
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
MX363558B (es) Composiciones farmaceuticas que comprenden flurbiprofeno.
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
IN2014MN01382A (es)
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
EA201590732A1 (ru) Диспергируемая таблетка